- Home
- ACLX vs SPR Comparison
ACLX vs SPR Comparison
Compare ACLX & SPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACLX
- SPR
- Stock Information
- Founded
- ACLX 2015
- SPR 1927
- Country
- ACLX United States
- SPR United States
- Employees
- ACLX N/A
- SPR N/A
- Industry
- ACLX Biotechnology: Pharmaceutical Preparations
- SPR Military/Government/Technical
- Sector
- ACLX Health Care
- SPR Industrials
- Exchange
- ACLX Nasdaq
- SPR Nasdaq
- Market Cap
- ACLX 4.4B
- SPR 4.3B
- IPO Year
- ACLX 2022
- SPR 2006
- Fundamental
- Price
- ACLX $90.01
- SPR $36.41
- Analyst Decision
- ACLX Strong Buy
- SPR Hold
- Analyst Count
- ACLX 8
- SPR 2
- Target Price
- ACLX $115.50
- SPR $38.63
- AVG Volume (30 Days)
- ACLX 427.8K
- SPR 1.2M
- Earning Date
- ACLX 11-05-2025
- SPR 10-31-2025
- Dividend Yield
- ACLX N/A
- SPR N/A
- EPS Growth
- ACLX N/A
- SPR N/A
- EPS
- ACLX N/A
- SPR N/A
- Revenue
- ACLX $35,898,000.00
- SPR $6,393,600,000.00
- Revenue This Year
- ACLX N/A
- SPR $21.51
- Revenue Next Year
- ACLX $220.95
- SPR $16.16
- P/E Ratio
- ACLX N/A
- SPR N/A
- Revenue Growth
- ACLX N/A
- SPR N/A
- 52 Week Low
- ACLX $47.86
- SPR $27.00
- 52 Week High
- ACLX $100.34
- SPR $42.33
- Technical
- Relative Strength Index (RSI)
- ACLX 57.21
- SPR 41.18
- Support Level
- ACLX $85.00
- SPR $35.17
- Resistance Level
- ACLX $91.68
- SPR $40.19
- Average True Range (ATR)
- ACLX 4.14
- SPR 0.82
- MACD
- ACLX -0.08
- SPR -0.01
- Stochastic Oscillator
- ACLX 71.76
- SPR 25.50
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
About SPR Spirit Aerosystems Holdings Inc.
Spirit AeroSystems manufactures aerostructures, particularly fuselages, cockpits, wing sections, engine pylons, and nacelles for commercial and military aircraft. The company was spun out of Boeing in 2005 to become the largest independent supplier of aerostructures for commercial aircraft. Boeing and Airbus are the firm's primary customers—Boeing represented roughly 60% and Airbus roughly 20% of revenue in recent years. The company is highly exposed to Boeing's beleaguered 737 program, which accounts for nearly half the company's revenue. The company plans to be acquired by and reintegrated into Boeing by the end of 2025.